Predictive Role of ERCC1 and XPD genetic polymorphisms in survival of Chinese non-small cell lung cancer patients receiving chemotherapy

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 6, 2012, Pages 2583-2586

  Zhang, Zhen Yong ^a   Tian, Xin ^a   Wu, Rong ^a   Liang, Yuan ^a   Jin, Xue Ying ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Chemotherapy; ERCC1; Non small cell lung cancer; Polymorphism; Prognosis; XPD

Indexed keywords

EID: 84874043473     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.6.2583     Document Type: Article

References (24)

1. Britten RA, Liu D, Tessier A, et al. (2000). ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells. Int J Cancer, 89, 453-7.
2. Bunn PA, Jr Kelly K, (1998). New chemotherapeutic agents prolong survival and improve quality of life in nonsmall cell lung cancer: a reviewof the literature and future directions. Clin Cancer Res, 4, 1087-100.
3. Chen J, Larochelle S, Li X, et al. (2003). Xpd/Ercc2 regulates CAK activity and mitotic progression. Nature, 424, 228-32.
4. Evans E, Moggs JG, Hwang JR, et al. (1997). Mechanism of open complex and dual incision formation by human nucleotide excision repair factors. EMBO J, 16, 6559-73.
5. Evans T, (2005). Chemotherapy in advanced non-small cell lung cancer. Semin Respir Crit CareMed, 26, 304-13.
6. (2008) International Agency for Research on Cancer. Lung cancer incidence, Mortality and Prevalence Worldwide in 2008. http://globocan.iarc.fr/factsheet.asp
7. Isla D, Sarries C, Rosell R, et al. (2004). Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced nonsmall-cell lung cancer. Ann Oncol, 15, 1194-203.
8. Kageyama T, Nagashio R, Ryuge S, et al. (2011). HADHA is a potential predictor of response to platinum-based chemotherapy for lung cancer. Asian Pac J Cancer Prev, 12, 3457-63.
9. Kiyohara C, Yoshimasu K, (2007). Genetic polymorphisms in the nucleotide excision repair pathway and lung cancer risk: a metaanalysis. Int J Med Sci, 4, 59-71.
10. Krivak TC, Darcy KM, Tian C, et al. (2011). Single nucleotide polypmorphisms in ERCC1 are associated with disease progression, and survival in patients with advanced stage ovarian and primary peritoneal carcinoma; a Gynecologic Oncology Group Study. Gynecol Oncol, 122, 121-6.
11. Lance C, McLennan G, Obuchowski N, et al. (2011). Comparative analysis of the safety and efficacy of transcatheter arterial chemoembolization and yttrium-90 radioembolization in patients with unresectable hepatocellular carcinoma. J Vasc Interv Radiol, 22, 1697-705.
12. Lord RV, Brabender J, Gandara D, et al. (2002). Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res, 8, 2286-91.
13. Metzger R, Leichman CG, Danenberg KD, et al. (1998). ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol, 16, 309-16.
14. (1995) Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a metaanalysis using updated data on individuals patients from 52 randomized clinical trials. Br Med J, 311, 899-909.
15. Olaussen KA, Dunant A, Fouret P, et al. (2006). DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med, 355, 983-91.
16. Ren S, Zhou S, Zhang L, et al. (2010). High-level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcome of platinum-based doublet chemotherapy of advanced nonsmall cell lung cancer patients. Cancer Invest, 28, 1078-83.
17. Rosell R, Fossella F, Milas L, (2002). Molecular markers and targeted therapy with novel agents: prospects in the treatment of non-small cell lung cancer. Lung Cancer, 38, 43-9.
18. Rosell R, Taron M, Ariza A, et al. (2004). Molecular predictors of response to chemotherapy in lung cancer. Semin Oncol, 31, 20-7.
19. Ryu JS, Hong YC, Han HS, et al. (2004). Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer, 44, 311-6.
20. Schiller JH, Harrington D, Belani CP, et al. (2002). Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl JMed, 346, 92-8.
21. Shirota Y, Stoehlmacher J, Brabender J, et al. (2001). ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol, 19, 4298-304.
22. Stoehlmacher J, Park DJ, Zhang W, et al. (2004). A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer, 91, 344-54.
23. Yan PW, Huang XE, Yan F, et al. (2011). Influence of MDR1 gene codon 3435 polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancer. Asian Pac J Cancer Prev, 12, 2291-4.
24. Zhang N, Lin LY, Zhu LL, et al. (2012). ERCC1 polymorphisms and risk of adult glioma in a Chinese population: a hospitalbased case-control study. Cancer Invest, 30, 199-202.